@inbook{cfcb09f85f6c42959ee6e0839d5d13aa,
title = "Immuno-Oncology for Gynecologic Malignancies",
abstract = "Patients with advanced and/or recurrent gynecologic cancers derive limited benefit from currently available cytotoxic and targeted therapies. Successes of immunotherapy in other difficult-to-treat malignancies such as metastatic melanoma and advanced lung cancer have led to intense interest in clinical testing of these treatments in patients with gynecologic cancers. Currently, in the realm of gynecologic oncology, the FDA-approved use of immune checkpoint inhibitors is limited to microsatellite instability-high cancers, cancers with high tumor mutational burden, and PD-L1-positive cervical cancer. However, there has been an exponential growth of clinical trials testing immunotherapy approaches both alone and in combination with chemotherapy and/or targeted agents in patients with gynecologic cancers.",
keywords = "Adoptive cell transfer, Cancer vaccines, Cervical cancer, Endometrial cancer, Immune checkpoint inhibitors, Immunotherapy, Ovarian cancer",
author = "How, {Jeffrey A.} and Ami Patel and Jazaeri, {Amir A.}",
note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive license to Springer Nature Switzerland AG.",
year = "2021",
doi = "10.1007/978-3-030-79308-1_6",
language = "English (US)",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer",
pages = "193--232",
booktitle = "Advances in Experimental Medicine and Biology",
}